News

VOQUENZA® provides quicker healing than Lansoprazole, according to an FDA-approved Phase 3 study

In this interview, Dr. Chovatiya responds to questions about the new FDA approval of secukinumab for patients with hidradenitis suppurativa.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments.

Patients with progressive DKD had greater gastrointestinal symptom scores than those with stable DKD.

Our October 2023 hepatology month in review features phase 2/3 data, updates in the hepatology pipeline, and other top news.

In this episode, hosts discuss the FDA clearance of the Omnipod 5 App for iPhones and a pair of studies examining use of automated insulin delivery systems.

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.

This segment of Dr. Kwatra’s latest interview featured a discussion on the future of prurigo nodularis treatment and the implications of his team’s research.

Patients with RAO had a higher risk of death, stroke, and myocardial infarction at both short-term and long-term intervals compared to matched controls diagnosed with cataract.

In this interview, Dr. Kwatra explored the recent phase 3 data from the Olympia 2 study on nemolizumab treatment for patients with prurigo nodularis.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

The risk of fractures was 14% greater in the group with patients with the autoimmune disease than the control group.

A study from investigators in Italy sheds further light on the relationship between physical activity and diabetic polyneuropathy risk in patients with type 1 diabetes.

Marla Dubinsky, MD, discusses findings from the LUCENT program and their role in the recent FDA approval of mirikizumab for ulcerative colitis.

12-month GATHER2 results show monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth than sham treatment.

These new results highlight the importance of further examining the link between cyberbullying, social pressures, academic performance, and eczema.

Biosimilars can be considerably cheaper for patients compared with the reference drug. Test your knowledge of when reference products can be swapped for biosimilars with this quiz.

This new data highlights the value of proper counseling regarding possible adverse effects prior to initiation of treatment initiation with JAK inhibitors.

Results from both phase 2 trials were presented in poster abstracts at ACG 2023.

On October 27, 2023, the FDA warned consumers to stop using ophthalmic products from 6 brands, including CVS Health and Rite Aid, after investigators found bacterial contamination at a manufacturing facility.

Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.

This case report from Brady Pregerson, MD, features a woman in her mid-60s presenting to the ER with generalized weakness and dyspnea. Can you determine the correct diagnosis?

Kremer discusses new ad hoc findings from the phase 3 ENHANCE trial showing seladelpar's unique effect on pruritus in patients with PBC.

Scleral buckling without PPV is effective for most patients with retinal dialysis and shows a low rate of cataract formation.

This interview with Dr. Feldman involved a discussion on new findings regarding atopic dermatitis patient preferences and racial disparities in dermatologic care.

This endocrine case report from Brady Pregerson, MD features a 32-year-old female with a history of polycystic ovary syndrome and diabetes who presents to the emergency department for sudden trouble swallowing, confusion, and shakiness. Can you determine the correct diagnosis?